Form 6-K NeuroSense Therapeutics For: Feb 08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of February 2023
Commission File Number: 001-41084
NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-799-6183
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On February 8, 2023, NeuroSense Therapeutics Ltd. (the “Company”) issued a press release announcing that Germany’s Federal Institute for Drugs and Medical Devices (BfArM) approved the Company’s Clinical Trial Application (CTA) to enroll patients in PARADIGM, its Phase 2b study of its lead combination drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). A copy of the press release is filed herewith as Exhibit 99.1.
Exhibit Index
Exhibit No. | Description | |
99.1 | Press Release, dated February 8, 2023 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NeuroSense Therapeutics Ltd. | ||
Date: February 8, 2023 | By: | /s/ Alon Ben-Noon |
Alon Ben-Noon | ||
Chief Executive Officer |
2
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- QuantaSing to Present at the AI & Technology Hybrid Investor Conference presented by Water Tower Research on April 10 and 11
- HEALWELL AI Reports Q4 and Full Year 2023 Financial Results
- CAPREIT Announces $216MM in Strategic Transactions
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!